Stock vs Stock Comparison

CRISPR Therapeutics AG vs AbbVie Inc.

ABBV wins the Tale of the Tape 7–2.

CRSP$52.08
ABBV$217.13

🏆 Tale of the Tape

27
CRSPABBV
Profitability (Net Margin)6.9%
Valuation (P/E)106.2x
-24.8%Efficiency (ROIC)8.3%
2/9Health (Piotroski F)7/9
7.4Safety (Altman Z)2.0
Growth (Rev YoY)8.6%
0.95Risk (Sharpe 1Y)0.61
0.18xBalance Sheet (D/E)-42.50x
-7.80%FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.178
252-Day Correlation
0.152
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricCRSPABBV
Market Cap$5.4B$384.7B
P/E Ratio106.2x
Forward P/E-14.5x13.4x
P/B2.98x-57.80x
Dividend Yield3.18%
Beta1.740.30

Quantitative Metrics

MetricCRSPABBV
DCF Fair Value$126.26
DCF Upside-38.9%
Piotroski F2/97/9
Altman Z7.392.01
Beneish M-2.87
FCF Yield-7.80%4.23%
Net Debt/EBITDA3.0x
ROIC-24.8%8.3%
WACC15.3%7.4%
ROIC – WACC-40.1pp0.8pp
Gross Margin70.2%
Net Margin6.9%
Rev Growth YoY8.6%
Sharpe (1Y)0.950.61
Max Drawdown 3Y-64.9%
FCF Payout Ratio65%

CRSP Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

CRSP found in:

ARKG8.28%
ARKK4.69%
XBI1.16%
VTWO0.14%
VXF0.06%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CRSP vs ABBV: Head-to-Head Analysis

CRISPR Therapeutics AG (CRSP) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABBV leads 7–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CRSP generates a return on invested capital (ROIC) of -24.8% compared to ABBV's 8.3%. This suggests ABBV is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between CRSP and ABBV is 0.178, indicating low correlation, making them an effective diversification pair in a portfolio context.

CRSP appears in 5 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CRSP or ABBV?

Our quantitative analysis compares CRSP and ABBV across nine fundamental dimensions. ABBV wins the Tale of the Tape 7–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CRSP and ABBV correlated?

The 252-day correlation between CRSP and ABBV is 0.178. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.